Datasets comprising simultaneous measurements of many essential metals in Alzheimer's disease (AD) brain 22 are sparse, and available studies are not entirely in agreement. To further elucidate this matter, we employed 23 inductively-coupled-plasma mass spectrometry to measure post-mortem levels of 8 essential metals and 24 selenium, in 7 brain regions from 9 cases with AD (neuropathological severity Braak IV-VI), and 13 controls 25 who had normal ante-mortem mental function and no evidence of brain disease. Of the regions studied, three 26 undergo severe neuronal damage in AD (hippocampus, entorhinal cortex and middle-temporal gyrus); three 27 are less-severely affected (sensory cortex, motor cortex and cingulate gyrus); and one (cerebellum) is relatively 28 spared. Metal concentrations in the controls differed among brain regions, and AD-associated perturbations in 29 most metals occurred in only a few: regions more severely affected by neurodegeneration generally showed 30 alterations in more metals, and cerebellum displayed a distinctive pattern. By contrast, copper levels were 31 substantively decreased in all AD-brain regions, to 52.8-70.2% of corresponding control values, consistent with 32 pan-cerebral copper deficiency. This copper deficiency could be pathogenic in AD, since levels are lowered to 33 values approximating those in Menkes' disease, an X-linked recessive disorder where brain-copper deficiency 34 is the accepted cause of severe brain damage. Our study reinforces others reporting deficient brain copper in 35 AD, and indicates that interventions aimed at safely and effectively elevating brain copper could provide a new 36 experimental-therapeutic approach. 37 38 Key words: Alzheimer's disease, dementia, neurodegeneration, human brain, metal homeostasis, brain-copper 39 deficiency, brain-zinc levels, brain-iron levels, superoxide dismutase 1, cytochrome c oxidase 40 41 89
Introduction

42
AD is the predominant cause of ageing-related dementia 1 . Some 35 million people world-wide were living with 43 dementia in 2010 and the estimated global prevalence will reach ~115 million affected individuals by 2050 2 . 44
Consequently, AD represents the largest unmet medical need in neurology 3 . 45 AD is characterized by the presence of extracellular amyloid-β (Aβ) plaques and intra-neuronal 46 neurofibrillary tangles formed from tau protein in affected regions of the brain. These aggregates have been 47 implicated in the causation of neuronal loss and neurodegeneration, which ultimately lead to the characteristic 48 global impairment of cognitive function but their role in pathogenesis remains unresolved and they may 49 represent phenomena down-stream from the aetiological insult(s) that cause the disease 4 . Moreover, 50 therapeutic interventions aimed at these protein-level phenomena have not yielded an effective disease-51 modifying therapy 5 . 52
Perturbed brain-metal homeostasis has been associated with cognitive decline and 53 neurodegeneration and hence may play a role in AD pathogenesis [6] [7] [8] [9] . However, the contribution of defective 54 metal regulation to the pathogenesis of AD is unresolved and no available therapy targeting metal metabolism 55 has an accepted place in the pharmacotherapy of AD 10 . The brain is a highly oxidative organ, and contains 56 abundant antioxidant mechanisms that may counteract the detrimental effects of reactive oxygen species 57 (ROS) produced during the reactions of redox-active transition metals with molecular oxygen, superoxide and 58 other oxygen-containing species 11 . Metals may not only affect rates of synthesis, degradation and clearance of 59
Aβ, but are also thought to play potential roles in the aggregation of Aβ and tau 7, 12 . Furthermore, as an 60 integral component of many metalloenzymes, transition metals can modulate the function of numerous 61 important pathways and, therefore, the metabolic processes they support 13 . Results of therapeutic 62 interventions aimed at Aβ or tau have been uniformly disappointing to date, so new ideas concerning the 63 pathogenesis of AD leading to identification of more tractable targets and interventions, are required to meet 64 the continuing unmet clinical need 5, 14 . 65
Previous studies investigating changes in metal concentrations in human AD-brain have typically 66
reported tissue content of one or a few metals (often iron (Fe), zinc (Zn), and/or copper (Cu)) in seriously 67 affected regions such as the hippocampus. Furthermore, results of studies comparing levels of metals in the 68 brains of AD patients and controls reported in the literature are somewhat heterogeneous 15 , possibly due to 69 experimental variability arising from factors such as differences in tissue processing: (e.g. fresh or formalin-70 fixed), handling, numbers of samples, and intrinsic variation in the distribution of metals in the brain tissue, 71 resulting perhaps from both compartmentalization and inter-regional differences 7, 16, 17 . Therefore, further 72 mapping of the regional distribution of metals in the brain is required to substantiate and extend our 73 understanding of the content of metals in various brain regions, and to associate these with region-specific 74 variation in AD pathology. As one example, Cu, Fe and Zn are enriched in amyloid plaques from AD brain 18, 19 : 75 by contrast, measurement of levels of these metals in whole-brain tissue from affected regions has yielded 76 somewhat inconsistent values 20, 21 . 77
To provide further evidence concerning the changes in concentration and regional distribution of 78 metals in brain from both non-demented aged and cases with AD, we report a study that we performed using 79 short-delay, fresh-frozen post-mortem human brain tissue by applying a validated inductively-coupled-plasma 80 mass spectrometry (ICP-MS) method 22 . We made parallel measurements of eight metals and selenium (Se), 81 and compared and contrasted results across seven functionally distinct brain regions from cases with AD and 82 matched controls without clinical dementia. Since some brain regions are more heavily affected by AD than 83 others 23 , we further aimed to contrast representative brain regions that are considered to be severely-affected: 84 hippocampus (HP), entorhinal cortex (ENT), and middle-temporal gyrus (MTG) 23, 24 ; moderately-affected: 85 sensory cortex (SCX), motor cortex (MCX), and cingulate gyrus (CG); along with one control region, cerebellum 86 (CB), which is relatively spared in the disease process 25, 26 . 87 88 Materials and methods provide rinse and calibration solutions, at 2% (v/v) final nitric acid concentration. Calibration solutions were 116 produced by appropriate dilutions of Environmental Calibration Standard (Agilent 5183-4688). 117
Acid digestion was carried out using an 'open-vessel' method. Tissue aliquots were briefly centrifuged 118 to ensure that the tissue sat at the bottom of the tube. The tube lids were punctured to prevent pressure 119 build-up, and 0.2 mL standard-containing nitric acid added. Tubes were then inserted into a "Dri-block" heater, 120
which was initially at room temperature. Plasma (SRM 1950) from the National Institute of Standards and 121 Technology (NIST), Gaithersburg, U.S.A was processed in parallel with experimental samples as standard 122 reference material ( Supplementary Table 1 ). Tubes with standard-containing acid but no sample were also 123 processed in each batch to provide "digestion" blanks ( Supplementary Table 2 ). Temperature was then set to 124 60 o C and the block switched on. After 30 min, the set temperature was increased to 100 o C, and digestion 125 continued for a further 210 min. After digestion, the tubes were allowed to cool overnight. 126
Aliquots of 100 μL were taken from each digestion and added to 15-mL Falcon tubes (Greiner) 127
containing 5-mL LC-MS grade water, to produce solutions for analysis at a final nitric acid concentration of 2% 128
(v/v). 129 calibration series was used as a periodic quality-control (QC) sample throughout each analytical batch. 145
Instrument and digestion blanks were also interspersed through each set of randomized samples. Detection 146 limit, limit of quantitation and background equivalent concentration for each physiological metal measured in 147 this study ( Supplementary Table 3 ) were automatically calculated by the software employed (Mass Hunter, 148 Agilent). 149 ICP-MS generates measurements of metals in their elemental states, from samples that have been 150 rendered into plasmas: therefore, where the result of an ICP-MS-based measurement is referred to in this 151 manuscript, the elemental symbol has been used (e.g. K for potassium). On the other hand, most metals are 152 present in the body as cations: therefore, when the physiological role(s) of metals and metal-related processes 153 are discussed, the symbol for the physiological cation has been employed (e.g. K + for the potassium ion, or 154 Cu(II) for the physiological divalent-Cu cation). 155
Data analysis 156
Datasets were exported to Microsoft Excel worksheets and individual values of each sample normalized by the 157 corresponding sample dry-weight. Weight-adjusted datasets were then log-transformed for statistical analysis. 158
Means (± 95% CI) of the log-transformed data were calculated and the significance of between-group 159 differences was examined by unpaired Welch's t-tests to allow for unequal variances and sample sizes. Means 160 (± 95% CI) were back-transformed to reflect the actual elemental concentrations of elements. Statistical 161 calculations were performed using GraphPad v6.04 (Prism; La Jolla, CA). P-values <0.05 have been considered 162 significant, and those of 0.05 ≤ P < 0.10 are also tabulated. 163
164
Results
165
We measured concentrations of eight essential metals, Na, Mg, K, Ca, Mn, Fe, Cu, and Zn, and the metalloid Se, 166 in seven regions of human post-mortem brains from nine AD cases and 13 controls matched for age and sex 167 (Table 1 , 2). Median (range) brain weight was 1062 g (831-1355) in the patient group and 1260 g (1094-1461; P 168 = 0.005) in the controls (Table 1 , 2): the ~16% decrease in mean brain weight in cases is consistent with the 169 histological severity 34 . The post-mortem delay in the AD group, 7 h (4.0-12.0), was significantly shorter than in 170 the control group 12 h (5.5-15.0; P = 0.005; Table 1 , 2). The AD group comprised sporadic cases only, as 171 determined by clinical, CERAD and Braak criteria. One control case also had neuropathological findings 172 consistent with early-stage AD (Braak II; Table 2 ) and was therefore diagnosed with premanifest disease: this 173 finding is consistent with the known frequency of asymptomatic AD in similarly-aged groups in the study 174 population 35 . Wet-wt/dry-wt ratios did not differ significantly between cases or controls (Table 1) . 175
In AD, measured Na levels were higher in severely affected regions (HP, ENT and MTG, where values 176 ranged from 0.55 to 0.59 mmol/kg dry-wt) compared with corresponding regions in control brains (whose 177 values ranged from 0.30 to 0.41 mmol/kg dry-wt; Table 3 -5). Mean Na levels were the highest in CB of 178 normal brain ( Fig. 1a , Table 3 -9) . 179
Mg levels were significantly higher in ENT and MTG, but lower in CB of AD-brain ( Fig. 1b , Table 4 -5, 180 9). In these brain regions, Mg concentrations were all around 0.03 mmol/kg dry-wt in AD-brain. However, in 181 normal brain, Mg levels varied among different brain regions. In the control brains, mean Mg concentrations 182 were highest in CB (0.036 mmol/kg dry-wt; Table 9 ), and much lower in ENT and MTG (0.025 -0.027 mmol/kg 183 dry-wt; Table 4 , 5). Similar to Na and Mg, K showed the highest mean concentrations in CB (0.56 mmol/kg dry-184 wt) in normal brain ( Fig.1c , Table 9 ). The mean concentration of K was the second highest in CG in the normal 185 brain (0.40 mmol/kg dry-wt; Fig. 1c , Table 8 ). Compared to normal brain tissue, levels of K were significantly 186 lowered in CG and CB of AD ( Fig.1c , Table 8 , 9) . 187
Compared to controls, mean concentrations of Ca in AD brain trended higher in all brain regions 188 except for CB (although values reached statistical significance only in ENT; Fig. 1d , Table 3 -9) . 189
In normal brain, mean Mn concentration was the highest in CB (45 μmol/kg dry-wt) and similar in all 190 other regions (23 -28 μmol/kg dry-wt; Fig. 1e , Table 3 -9). In AD, Mn levels were significantly higher in HP 191 (Table 3) but lower in CB (Table 9 ). In control brain, Se concentrations were highest in CB (23 μmol/kg dry-wt), 192 and second highest in CG and MTG (14 μmol/kg dry-wt), whereas the rest of the brain regions fell within the 193 range of 11 -13 μmol/kg dry-wt ( Fig. 1f , Table 3 -9) . In AD tissue, Se levels were significantly lower in CG (9.3 194 μmol/kg dry-wt) and CB (14 μmol/kg dry-wt) when compared to controls In normal brain, Fe levels were highest in CB (6.1 mmol/kg dry-wt) and lowest in HP (3.7 mmol/kg dry-196 wt; Fig. 1g , Table 3 -9). AD tissue showed significantly higher levels of Fe in HP, ENT, and MTG (Table 3 - 5), 197 whereas no significant differences were observed in other brain regions. Interestingly, mean Fe levels were 198 lower in CG and CB in AD compared to controls ( Zn concentrations were highest in CB (1.9 mmol/kg dry-wt) and HP (1.3 mmol/kg dry-wt; Fig. 1h , Table 1 -9) . 201
Mean Cu concentrations in controls were highest in CB (710 μmol/kg dry-wt) and lowest in ENT (310 202 μmol/kg dry-wt). Remarkably, Cu levels were significantly decreased in all seven regions of AD-brain compared 203 with corresponding controls (Fig. 1i , Table 3 
Discussion
210
Here we report measurements of physiologically-essential metal concentrations in seven regions of post-211 mortem brain in cases with AD and controls matched for age and male-to-female ratio, whose ante-mortem 212 brain structure and function had been assessed as normal. Although post-mortem tissue metal values may be 213 affected by ion gradients between cells and extracellular compartments, they are neither metabolized nor 214 exchanged with other tissues after death, due to cessation of blood circulation. There is no pronounced 215 correlation between post-mortem delay and tissue metal content: hence, it has been suggested that total 216 brain-tissue metal content does not change significantly after death 36 . Therefore, the relatively small 217 differences in post-mortem delay between case and control groups in this study are unlikely to have affected 218 the accuracy of our measurements and hence, the validity of comparisons between AD and control groups. 219
The maintenance of physiological intracellular Na + and K + levels is critical for controlling the 220 homoeostasis of cell volume and prevention of apoptosis 37 . The marked increase of Na levels in the most-221 affected regions of AD-brain (HP, ENT, and MTG) observed here is consistent with another report of increased 222
Na concentrations in AD in the medial temporal lobes 38 , and frontal and parietal cortex 36 . We also observed, in 223 moderately affected regions (MCX, SCX, and CG), that there were non-significant trends towards increased Na 224 levels. Na levels in CB did not differ between groups, consistent with another report that cerebellar Na levels 225 did not differ between post-mortem human AD and control brain 36 . Increased Na content has also been 226 inversely correlated with brain volume in the HP 38 . Therefore, given that heavily-affected brain regions 227 reportedly undergo volume losses at greater rates during disease progression 39 , our observation is consistent 228 with the idea that Na + levels increase in regions of severe neurodegeneration/volume loss in AD, perhaps due 229 to diminished energy supply required for aspects of cell-Na + homeostasis. 230
Shrinkage of grey matter is commonly regarded as a consequence of neuronal cell death 40 . Cell death 231 and cell shrinkage are distinguishable processes that are intrinsically linked, in that cell shrinkage is a universal 232 feature of apoptosis that is conserved among species. Intracellular Na + reportedly increases transiently to 233 initiate apoptotic signalling prior to cell-volume loss, and a significant decrease in intracellular K + and Na + is 234 known to occur during apoptotic cell-shrinkage 37, 41 . Whether the elevation in Na levels observed here is 235 associated with neuronal apoptosis is undetermined. While a previous study has reported decreased brain K 236 levels in AD 42 , here we found no changes of K levels in the severely affected regions of AD-brain. Instead, we 237 identified significant lowering of K in CG and CB, at possible variance with a reported increase in K 238 concentration in CB of AD-brain 36 . It was also suggested that K + efflux mediates cell death by apoptosis 37, 43 . 239
Consistently, our observations may represent a result of K + efflux associated with apoptosis in these regions 240 prior to death in AD patients, possibly due to insufficient energy supply to maintain K + homeostasis. CSF levels 241 of Na and K did not differ between AD cases and controls in another report 36 , consistent with the altered 242 concentrations of both metals observed in our current study, which may reflect changes in the concentrations 243 of both in the intracellular compartment. 244
Neuronal Mg 2+ not only participates in energy production (e.g. as a component of purine nucleoside 245 complexes), intracellular signalling and synaptic neurotransmission, but also modulates synaptic density and 246 plasticity 44 . Mg 2+ displays a non-homogeneous distribution among different regions of normal brain, and 247 significant decreases have been reported in AD 45 . Here we found that brain Mg showed a heterogeneous 248 distribution, with CB having the highest levels in normal brain. In AD however, Mg concentrations were 249 increased in ENT and MTG but relatively decreased in CB, resulting in a more homogenous distribution of Mg 250 across different brain regions as compared with normal brain. Prolonged exposure to elevated Mg 2+ is said to 251 exert an overall inhibitory effect on neuronal transmission resulting in decreased neuronal survival 44 , which 252 could be consistent with increased Mg levels in the heavily affected regions of ENT and MTG. On the contrary, 253
whether the markedly decreased Mg concentration in the CB is associated with improved neuronal survival 254 remains uncertain. 255
Calcium homeostasis is critical for maintenance of normal brain function since Ca 2+ ions mediate 256 neuronal signal transduction and modulate processes including synaptic plasticity and apoptosis 46-48 . 257 Characteristic lesions of AD have been associated with increased intracellular Ca 2+ , including Aβ accumulation, 258 tau hyperphosphorylation, and neuronal death 48 . Excessive Ca 2+ is implicated as a cause of acute neuronal 259 injury, possibly through neurotoxicity induced by excitatory amino acids 47, 49 . Here, Ca levels were significantly 260 increased only in ENT, possibly reflecting a Ca 2+ -associated neurotoxicity localized in this brain region, which is 261 known to be an initial site of neurodegeneration in AD. Our findings also suggest alteration in total Ca 262 concentrations in the affected regions of AD tissue following progressive neurodegeneration, although they do 263 not exclude the possibility that disturbed Ca 2+ homeostasis occurs before neurodegeneration. 264
As an important antioxidant, Se plays a protective role against oxidative stress, and its concentration 265 is well-maintained by the brain, even during dietary Se deficiency 50 . Se deficiency has been correlated with 266 altered cognitive function 51, 52 and decreased serum and plasma Se is reported in AD 53-55 . However, systematic 267 examination of Se levels in AD-brain has not been reported to our knowledge. Here we found that Se 268 concentrations were not altered in the heavily or moderately affected brain regions. Rather, significant 269 decreases were observed in CG and CB of AD-brain. This finding may be consistent with previously observed 270 co-localization of the Se-transport protein, selenoprotein P, with Aβ plaques and neurofibrillary tangles 56 , 271 possibly serving as a compensatory mechanism to maintain Se levels in affected locations in AD brain. 272
Oxidative damage is an important aspect of AD pathology. Cu, Zn and Mn participate in oxidative 273 defence mechanisms as necessary components of the superoxide dismutase (SOD) enzymes, including Mn-SOD 274 (SOD2), present mainly in mitochondria 57 , and two Cu/Zn-SODs (SOD1, SOD3), present respectively in the 275 cytosol and mitochondria, and in the extracellular space 58 . 276
Mitochondrial oxidative damage and impaired energy production are considered to be early 277 pathological events that lead to neurodegeneration. Mice with brain-specific Mn-SOD deficiency exhibit 278 spongiform neurodegeneration of the brain accompanied by increased lipid peroxidation 59 and Mn-SOD may 279 play a protective role against apoptosis and neuronal degeneration 60 . Furthermore, Mn-deficient animals 280 exhibit depressed Mn-SOD, with associated increase in lipid peroxidation 61 . Additionally, Mn excess confers 281 neurotoxicity in the central nervous system, through both oxidative damage and involvement of Mn in the 282 activation of the enzyme glutamine synthetase and therefore, in glutaminergic and GABAergic 283 neurotransmission 62, 63 . Previous studies reported decreased serum Mn levels in AD patients 55 . However, data 284 concerning altered brain levels of Mn remain inconclusive in the current literature; independent studies have 285 reported either increased Mn levels 64 or no significant alteration 65 in Mn levels in AD post mortem brain. This 286 is not surprising considering the inter-regional difference in Mn levels in the brain as observed in this study. 287
Our results indicate that Mn homeostasis is disturbed in both HP and CB, but evidently in opposite directions, 288 since Mn levels were increased in HP and decreased in CB of AD-brain. Also, acting through mitochondrial 289 electron transport chain (mETC) complex II, Mn reportedly elicits mitochondrial hydrogen peroxide 290 production 66, 67 . The increase in Mn concentration observed here in the HP could be associated with severe 291 neurodegeneration through increased oxidative stress via this mechanism. 292
The metal hypothesis of AD pathogenesis was originally built upon a triad of altered homeostasis of 293 the transition elements: Fe, Zn and Cu. In AD brain, dysregulation of metal homeostasis is postulated to 294 engender amyloidogenic and oxidative stress as a consequence, and, in reverse, AD-related proteins (for 295 example, APP and tau) may play significant roles in brain-metal regulation 8, 16 . Previous studies reported 296 elevated levels of iron 68 and zinc 69 in extracts of AD brain and increased levels of labile Fe in the serum of AD 297 patients 55 . Furthermore, Fe levels were reported to be markedly increased in degenerating regions of AD 298 brain 70 . Here we also found significant increases in Fe and Zn levels that were localized in heavily affected 299 regions. This effect could possibly be associated with overall load of plaques and tangles in these regions, 300
considering the reported enrichment of Fe and Zn in and around amyloid plaques in AD 19 . Decreased 301 transferrin in cortex may impair brain-Fe utilization and subsequently drive oxidative damage and neuronal 302 degeneration in affected regions 71 . 303
In the brain, Zn 2+ is co-localized with glutamate and modulates both excitatory and inhibitory 304 neurotransmission 72 . Zn 2+ not only elicits potential roles as a (putative) neurotransmitter and modulator of 305 synaptic plasticity, but is also thought to play a potential role in AD pathogenesis related to its interactions 306 with APP and Aβ, reportedly participating in APP processing, Aβ aggregation and Aβ clearance. Enrichment of 307
Zn in the core of Aβ plaques might disrupt Zn homeostasis in brain regions important for memory and 308 vulnerable to AD pathogenesis 73, 74 . Our observations of increased Zn in ENT and MTG mirrors previous reports 309 of its elevation in AD brain 69 , which may accord with the (proposed) increase of Zn 2+ -sequestration in heavily 310 affected brain regions, potentially leading to functional unavailability of Zn 2+ required for physiological 311 processes, regardless of any increase in total tissue-Zn. Whether or how the previously reported decrease in 312 serum Zn levels in AD 55 is associated with altered brain-Zn regulation is unclear. A previous study has 313 suggested that HP may contain the highest Zn content among those brain-regions examined 17 : consistently, we 314
found Zn levels to be higher in HP than other regions, although they approximated those in CB. 315
Cu is a necessary component of certain metalloenzymes that play key roles in essential metabolic 316 processes such as energy metabolism, antioxidant-defence mechanisms, Fe metabolism, and neurotransmitter 317 synthesis 75 . It is still controversial as to whether it is Cu excess or Cu deficiency that might contribute to the 318 pathogenesis of AD 76 . Here we found Cu levels to be significantly depressed in all seven regions of AD-brain 319 examined (Fig. 1 ). There are several reports that tissue-Cu concentration is decreased in several regions of 320 post-mortem brain in AD 68, 69 . These findings, taken together, are consistent with reported depression of 321 cytochrome C oxidase (COX) activity in mitochondria isolated from AD-brain 77 . COX is a metalloenzyme that 322 acts at the terminus of the mitochondrial respiratory chain (in complex IV); its catalytic core is formed by three 323 subunits encoded by the mitochondrial genome: two of these, COI and COII, which cooperate to catalyse the 324 reduction of molecular oxygen to form water, are linked Cu enzymes that together contain three bound Cu 325 atoms. Marked decreases in tissue-Cu content will not only have a significant impact on cellular energy 326 production, but are also likely to facilitate increased oxidative damage in the AD-brain by impairing Cu-327 mediated antioxidant defences, for example that catalysed by SOD1. Cu also plays roles in regulation of other 328 transition metals: therefore, the possibility that altered Cu homeostasis in AD could play roles in observed 329 alterations in levels of some of the other transition metals merits consideration. 330
Increased concentrations of caeruloplasmin (the major plasma ferroxidase and Cu-containing protein in 331 plasma) in HP, ENT and frontal cortex of AD-brain, have been suggested to represent a localized acute phase-332 type response and/or a compensatory increase to counter oxidative stress 78 . In AD patients, caeruloplasmin-333 copper dysregulation has been associated with elevated labile-Cu levels in the blood 55, 76, 79 . In light of this 334 observation, global decreases in brain Cu as observed in this study, combined with previously-described Cu 335 enrichment in and around amyloid plaques in AD-brain 19 , have been interpreted as consistent with marked 336 depletion of Cu-availability for normal cellular functions (such as energy production and anti-oxidant defence) 337 in all brain regions examined in the current study. 338
Another interesting pattern is evident in our data. There were markedly higher levels of Cu in the 339 normal CB, compared to all other brain regions examined. It is noteworthy that the metal concentrations in 340 normal CB measured in this study (on a wet-weight basis) are consistent with CB metal concentrations 341 previously reported (for Cu, Fe, Zn, Mn, and Se only) 80 . The intrinsically higher levels of several metals 342 measured in CB, including Ca, Mg, Zn, Fe and Cu may be attributable to higher mitochondrial density in this 343 region. Consistently, AD-brain reportedly exhibits significant reduction in mitochondrial membrane fluidity in 344 cerebral regions that may result from lipid peroxidation: the exception to this observation was noted to be the 345 CB 81 . 346
What might be the significance of lowered brain Cu in AD? Cu plays central roles in antioxidant 347 defence via its structural and functional actions in SOD1, SOD3, and COI and COII. We have previously shown 348 that, in the context of diabetic cardiomyopathy (DCM, another chronic disease linked to altered Cu regulation), 349 deficient cardiac Cu impairs antioxidant defences that are restored by drug treatment, thereby establishing the 350 pathogenic action of lowered tissue Cu 58, 82 . In DCM, lowering of myocardial Cu may be caused by the action of 351 divalent Cu bound to N-ε-carboxymethyllysine (CML) groups in modified collagen, to suppress CTR1-mediated 352
Cu uptake, leading to deficient Cu insertion into metalloenzymes 82-84 . The depression in brain-Cu levels in AD is 353 similar to that in the diabetic heart 82 , and may well be caused by a similar mechanism; for example, 354 extracellular CML is also elevated in AD 85 , where it could well serve as a marker for this Cu-related pathogenic 355 process 84 . Therefore, these low brain-Cu levels are consistent with the causation of neurodegeneration and 356 may well be pathogenic in AD. 357 Lowered brain-Cu levels, measured here in AD cases, approximate to those reported in Menkes' disease, an X-358 linked recessive disorder caused by mutation in ATP7A, which encodes a Cu-transporting ATPase, causing 359 severe neurodegeneration via brain-Cu deficiency 86 . Similar lowering of brain Cu with neurodegeneration also 360 occurs in animals with spontaneous or induced mutations in Atp7a 87 . Metabolic studies reveal that trafficking 361 of ATP7A after NMDA (N-methyl-D-aspartate) receptor activation triggers rapid release of copper ions from 362 hippocampal neurons; ATP7A is directly required for this copper efflux, because parallel studies in 363 hippocampal neurons derived from mice lacking functional ATP7A do not release copper 88 . Thus, ATP7A plays 364 a critical role in the availability of an NMDA receptor-dependent, releasable pool of copper in hippocampal 365 neurons and affords a unique mechanism linking copper homeostasis to neuronal activation in the central 366 nervous system. In addition, NMDA receptor activity is modulated by cellular prion protein (PrPC) in a copper-367 dependent manner 89 . Moreover, copper ions potently modulate NMDA-receptor kinetics via modulation of 368 PrP C , providing a mechanism that potentially links defective copper regulation to neurodegeneration. Thus, 369 disruption of the NMDA synaptic system could provide a mode of copper dysregulation in AD. Furthermore, 370
brain-Cu deficiency also causes neurodegeneration in other contexts, for example, insufficient dietary-Cu 371 uptake 90-93 . Taken together, these observations suggest that a treatment that can safely and effectively restore 372 brain Cu might exert beneficial effects in the treatment of AD 10 . However, elevating oral Cu intake had no 373 effect on cognition in patients with mild AD in a pilot phase 2 clinical trial 94 although, in that study, restoration 374 of brain-Cu levels was not demonstrated. An effective method for in vivo measurement of brain Cu would be 375 helpful for monitoring future intervention trials that aim to restore brain Cu but, to our knowledge, such a 376 method is not yet available. Also required is an effective means of therapeutically raising brain-Cu levels: in 377 this regard, the divalent-Cu-selective chelator, triethylenetetramine demonstrably elevates tissue Cu in 378 another metabolic context, namely localized myocardial Cu deficiency in diabetic cardiomyopathy 10, 82, 95 . 379 Recent data demonstrating severe diabetes-like metabolic perturbations in the brain in AD may also be 380 relevant to this objective 9, 96 . 381
In conclusion, we have presented a study of post-mortem levels of nine essential elements in seven 382 regions of the human brain in cases of AD and matched controls. The inter-regional difference in metal 383 concentrations in both diseased and healthy brains as observed in this study: 1) demonstrates the importance 384 of spatial resolution when studying a complex organ such as brain, and 2) provides potential explanations for 385 some of the apparently differing findings in the literature. AD-associated alterations in metal homeostasis 386 were evident in all brain regions studied, but changes in metals other than Cu were present only in a subset. By 387 contrast, these data provide compelling evidence for pan-cerebral Cu deficiency in AD. Widespread brain-Cu 388 deficiency may well contribute to the pathogenesis of neurodegeneration and dementia, probably acting via 389
Cu-deficiency-induced defects in energy utilization and anti-oxidant defences. We propose that new 390 therapeutic interventions that can safely and effectively restore brain Cu levels, could have a place in the 391 experimental therapeutics of Alzheimer's dementia. 392
393
Acknowledgments and Sources of Support 394
We thank Cynthia Tse and Michael Anderson for their assistance with the management of these studies. We 395 acknowledge Professor Sir John Scott for his encouragement, moral support, and helpful discussions with us, 396 and thank the families of patients who supported this research through their donation of brains to the New 397 
Duality of Interest Statement 411
GJC is named as inventor in patents that disclose the use of the Cu-selective chelator, triethylenetetramine 412 (TETA) for the treatment of diabetic organ damage: these have been assigned and he has no financial interest 413 in them. All other authors declare no duality of interest. 414 Abbreviations: GI, gastrointestinal; MI, myocardial infarction; PMD, post-mortem delay; wt, weight. Cause of death was determined by post-mortem examination, and brain pathology and Braak Stage were assigned by specialist neuropathological examination. Causes of death were the primary causes listed on the death certificate. Patient H241 was found to have post-mortem signs consistent with AD and was therefore diagnosed with prodromal disease: data corresponding to this patient have been retained in the main analysis presented in this manuscript. Data are means (± 95% CI); P-values for significance of between-group differences were calculated by Welch's ttests based on measurements from control (n=13) and AD (n=9) brains. Data are means (± 95% CI); P-values for significance of between-group differences were calculated by Welch's ttests based on measurements from control (n=13) and AD (n=9) brains. Data are means (± 95% CI); P-values for significance of between-group differences were calculated by Welch's ttests based on measurements from control (n=13) and AD (n=9) brains. Data are means (± 95% CI); P-values for significance of between-group differences were calculated by Welch's ttests based on measurements from control (n=13) and AD (n=9) brains. Data are means (± 95% CI); P-values for significance of between-group differences were calculated by Welch's ttests based on measurements from control (n=13) and AD (n=9) brains. Data are means (± 95% CI); P-values for significance of between-group differences were calculated by Welch's ttests based on measurements from control (n=9) and AD (n=9) brains. Data are means (± 95% CI); P-values for significance of between-group differences were calculated by Welch's ttests based on measurements from control (n=13) and AD (n=8) brains. Aliquots of plasma (SRM 1950) from the National Institute of Standards and Technology (NIST, Gaithersburg, U.S.A.) were processed with sample batches to provide a standard reference material. NIST SRM 1950 aliquots of 50 µl were digested and processed in the same way as samples. The standard material provides certified reference values for Na, Mg, K, Ca, Cu, Zn and Se in the units given in the table. All measurements across multiple batches were within 5% of the certified values except for zinc, which was 6.26%. The %CV across these batches was less than 5% for all metals. (µg/L) <0.000 indicates that a sample concentration was lower than that of the calibration blank. Samples were analysed across three batches. Each sample batch included two digestion blanks, and tubes containing standard-containing acid but no sample to ensure background levels from processing were not high enough to interfere with sample quantification. A blank batch consisting of 25 digestion blanks was analysed in order to assess the variability of metal levels across individual tubes as also used for tissue digestion. Whilst some variability between different tubes was observed, for most metals the highest blank was still less than 5% of the lowest sample measured across all of the sample batches. The exceptions were calcium and manganese where the highest blanks were 6.55% and 6.93% of the lowest samples respectively; these values are nevertheless indicative of excellent analytical capability of these methods. For sodium, magnesium, potassium and calcium the highest blanks occurred in samples run immediately after QC samples so are likely higher due to carryover rather than higher background levels in the corresponding tubes.
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